A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, formerly PT2977) Monotherapy in Participants With Advanced Pheochromocytoma/Paraganglioma (PPGL) , Pancreatic Neuroendocrine Tumor (pNET), von Hippel-Lindau (VHL) Disease-Assoc…

The main inclusion criteria include but are not limited to the following:
*  Male and female participants at least 12 years of age (at least 18 years of age for Cohort B1)
*  Diagnosis of one of the following: Advanced/metastatic pheochromocytoma/paraganglioma (PPGL), pancreatic neuroendocrine tumors (pNET), von Hippel-Lindau (VHL) disease associated localized tumors, or advanced wild-type gastrointestinal stromal tumor (wt GIST) or advanced solid tumors with Hypoxia Inducible Factor- 2 alpha subunit (HIF-2α) related genetic alterations
*  Cohort BI: VHL Disease-associated tumors:
*  Have a diagnosis of VHL disease as determined by a germline test locally and/or clinical diagnosis
*  Must be ≥18 years of age
*  Has a life expectancy of at least 3 months The main exclusion criteria include but are not limited to the following:
*  Unable to swallow orally administered medication or has a disorder that might affect the absorption of belzutifan
*  History of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years
*  Any of the following: A pulse oximeter reading \<92% at rest, or requires intermittent supplemental oxygen, or requires chronic supplemental oxygen
*  Clinically significant cardiac disease, including unstable angina, acute myocardial infarction, or arterial bypass (CABG) or Percutaneous transluminal coronary angioplasty (PTCA) ≤6 months from study entry, or New York Heart Association Class III or IV congestive heart failure
*  Received prior treatment (except somatostatin analogs) with chemotherapy, targeted therapy, biologics, or other investigational therapy within the past 4 weeks of first dose of study intervention